Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGC738 in advanced ccRCC
NCT06870279Phase 1Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CGC-738 in clear cell renal cell carcinoma (ccRCC), sponsored by Renji Hospital. Primary endpoint: Dose Limiting Toxicities at Day 28. Planned start May 2025; status: not yet recruiting.
02
Drugs
CGC-738
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06870279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870279.